Haoxi Health Technology Releases Financial Results for Six Months Ending December 2024

An update from Haoxi Health Technology Limited Class A ( (HAO) ) is now available.

On April 23, 2025, Haoxi Health Technology Limited released its unaudited condensed consolidated financial statements for the six months ended December 31, 2024, and 2023. The financial report highlights a slight increase in revenues compared to the previous year, with a notable decrease in gross profit due to higher costs of revenues. The company’s operating expenses have risen, primarily driven by increased general and administrative costs. This financial update provides stakeholders with insights into the company’s current financial health and operational challenges.

Spark’s Take on HAO Stock

According to Spark, TipRanks’ AI Analyst, HAO is a Neutral.

Haoxi Health Technology Limited is experiencing strong revenue growth and profitability improvement, which are significant strengths. However, the stock faces challenges with weak cash flow management and bearish technical indicators. The high P/E ratio reflects high market expectations, but the lack of dividend yield may concern income-focused investors. Overall, the stock is positioned for growth but requires improvements in cash flow and profitability for sustained performance.

To see Spark’s full report on HAO stock, click here.

More about Haoxi Health Technology Limited Class A

Haoxi Health Technology Limited operates within the health technology industry, focusing on providing innovative health solutions and services. The company is based in Beijing, China, and is involved in developing and delivering health-related technology products.

YTD Price Performance: -69.33%

Average Trading Volume: 136,049

Technical Sentiment Signal: Strong Buy

For detailed information about HAO stock, go to TipRanks’ Stock Analysis page.